{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:06:17Z","timestamp":1719187577715},"reference-count":15,"publisher":"Informa UK Limited","issue":"sup1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.2217\/fon-2019-0600","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T13:38:54Z","timestamp":1579873134000},"page":"33-38","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A Case of Eribulin-Induced Regression of Liposarcoma of the Left Funiculus in a Heavily Pretreated Patient"],"prefix":"10.1080","volume":"16","author":[{"given":"Salvatora Tindara","family":"Miano","sequence":"first","affiliation":[{"name":"Oncology Unit, Policlinico Santa Maria Alle Scotte,Universit\u00e0 degli Studi di Siena,\rSiena,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Francini","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Misericordia Hospital,\rGrosseto,\rItaly"},{"name":"Department of Medical\u2013Surgical Sciences & Translational Medicine,University of Rome \u201cLa Sapienza\u201d,\rRome,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Petrioli","sequence":"additional","affiliation":[{"name":"Oncology Unit, Policlinico Santa Maria Alle Scotte,Universit\u00e0 degli Studi di Siena,\rSiena,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Francini","sequence":"additional","affiliation":[{"name":"Oncology Unit, Policlinico Santa Maria Alle Scotte,Universit\u00e0 degli Studi di Siena,\rSiena,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1344098"},{"key":"e_1_3_4_4_1","unstructured":"National Comprehensive Cancer Network . National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: NCCN guidelines: Soft tissue sarcoma (2019). www.nccn.org\/professionals\/physician_gls\/default.aspx"},{"key":"e_1_3_4_5_1","volume-title":"WHO Classification of Tumours of Soft Tissue and Bone (ed 4)","author":"Fletcher CDM","year":"2013","unstructured":"Fletcher CDM , BridgeJA, HogendoornP, MertensF. WHO Classification of Tumours of Soft Tissue and Bone (ed 4). IARC Press, Lyon, France (2013)."},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu254"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020294"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3252"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi901810u"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12488"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.80"},{"issue":"4","key":"e_1_3_4_12_1","first-page":"1553","article-title":"Antimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcoma","volume":"36","author":"Kawano S","year":"2016","unstructured":"Kawano S , AsanoM, AdachiY, MatsuiJ. Antimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcoma. Anticancer Res.36(4), 1553\u20131561 (2016).","journal-title":"Anticancer Res."},{"key":"e_1_3_4_13_1","unstructured":"Eisai: Halaven (eribulin mesylate) injection [prescribing information]. Eisai Woodcliff Lake NJ (2016)."},{"key":"e_1_3_4_14_1","unstructured":"Eisai: Halaven 0.44 mg\/ml solution for injection [summary of product characteristics]. Eisai Europe Limited Hertfordshire UK."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01283-0"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz096"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13661"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:02Z","timestamp":1719125162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":15,"journal-issue":{"issue":"sup1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.2217\/fon-2019-0600"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0600","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}